Bleakley Financial Group LLC Trims Holdings in Esperion Therapeutics, Inc. (NASDAQ:ESPR)

Bleakley Financial Group LLC trimmed its position in Esperion Therapeutics, Inc. (NASDAQ:ESPR) by 20.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 24,398 shares of the biopharmaceutical company’s stock after selling 6,104 shares during the quarter. Bleakley Financial Group LLC’s holdings in Esperion Therapeutics were worth $73,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of ESPR. Wasatch Advisors LP raised its position in Esperion Therapeutics by 95.0% during the first quarter. Wasatch Advisors LP now owns 13,354,186 shares of the biopharmaceutical company’s stock valued at $21,233,000 after acquiring an additional 6,505,808 shares in the last quarter. Armistice Capital LLC purchased a new position in Esperion Therapeutics during the first quarter valued at approximately $5,850,000. Jacobs Levy Equity Management Inc. raised its position in Esperion Therapeutics by 429.3% during the third quarter. Jacobs Levy Equity Management Inc. now owns 2,264,359 shares of the biopharmaceutical company’s stock valued at $2,219,000 after acquiring an additional 1,836,567 shares in the last quarter. Wasatch Advisors Inc. raised its position in Esperion Therapeutics by 27.6% during the first quarter. Wasatch Advisors Inc. now owns 8,147,380 shares of the biopharmaceutical company’s stock valued at $37,804,000 after acquiring an additional 1,761,117 shares in the last quarter. Finally, Millennium Management LLC raised its position in Esperion Therapeutics by 116.8% during the second quarter. Millennium Management LLC now owns 2,706,290 shares of the biopharmaceutical company’s stock valued at $17,212,000 after acquiring an additional 1,457,952 shares in the last quarter. 47.39% of the stock is currently owned by hedge funds and other institutional investors.

Esperion Therapeutics Price Performance

Shares of NASDAQ:ESPR opened at $1.91 on Wednesday. The business’s 50 day moving average price is $2.52 and its 200-day moving average price is $1.94. The firm has a market capitalization of $361.75 million, a PE ratio of -0.90 and a beta of 0.84. Esperion Therapeutics, Inc. has a 1 year low of $0.70 and a 1 year high of $3.40.

Esperion Therapeutics (NASDAQ:ESPR) last issued its quarterly earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.03. The firm had revenue of $32.25 million during the quarter, compared to analyst estimates of $26.84 million. During the same period in the prior year, the firm earned ($0.76) earnings per share. As a group, analysts expect that Esperion Therapeutics, Inc. will post -0.68 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts recently weighed in on the company. HC Wainwright reiterated a “buy” rating and set a $16.00 price target on shares of Esperion Therapeutics in a research report on Monday, March 25th. Needham & Company LLC reissued a “buy” rating and issued a $8.00 price objective on shares of Esperion Therapeutics in a report on Wednesday, April 10th. Finally, Bank of America lowered Esperion Therapeutics from a “buy” rating to a “neutral” rating in a report on Wednesday, January 3rd. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $9.33.

Esperion Therapeutics Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.